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Aims
In a multicentre, randomised study of adolescents undergoing posterior spinal fusion for 
idiopathic scoliosis, we investigated the effect of adding gelatine matrix with human 
thrombin to the standard surgical methods of controlling blood loss.
Patients and Methods
Patients in the intervention group (n = 30) were randomised to receive a minimum of two 
and a maximum of four units of gelatine matrix with thrombin in addition to conventional 
surgical methods of achieving haemostasis. Only conventional surgical methods were used 
in the control group (n = 30). We measured the intra-operative and total blood loss (intra-
operative blood loss plus post-operative drain output).
Results
Each additional hour of operating time increased the intra-operative blood loss by 356.9 ml 
(p < 0.001) and the total blood loss by 430.5 ml (p < 0.001). Multiple linear regression 
analysis showed that the intervention significantly decreased the intra-operative (-171 ml, 
p = 0.025) and total blood loss (-177 ml, p = 0.027). The decrease in haemoglobin 
concentration from the day before the operation to the second post-operative day was 
significantly smaller in the intervention group (-6 g/l, p = 0.013) than in the control group. 
Conclusion
The addition of gelatine matrix with human thrombin to conventional methods of achieving 
haemostasis reduces both the intra-operative blood loss and the decrease in haemoglobin 
concentration post-operatively in adolescents undergoing posterior spinal fusion for 
idiopathic scoliosis.
Take home message: A randomised clinical trial showed that gelatine matrix with human 
thrombin decreases intra-operative blood loss by 30% when added to traditional surgical 
haemostatic methods in adolescents undergoing posterior spinal fusion for idiopathic 
scoliosis.
Cite this article: Bone Joint J 2016;98-B:395–401.
Surgery for adolescent idiopathic scoliosis
(AIS) can be associated with major blood
loss.1-3 Predictors of the need for allogeneic
blood transfusion in these patients are the use
of a posterior approach, patients in whom
nine or more levels are to be fused and those
with additional comorbidities.3 Bleeding from
highly vascular paraspinal muscles, cancel-
lous bone or epidural venous plexus may
require allogeneic or autologous blood trans-
fusions, given that most patients with adoles-
cent idiopathic scoliosis typically undergo
posterior spinal fusion of nine or more
levels.3,4 Peri-operative allogeneic blood
transfusion increases the risk of post-
operative infection and transfusion reactions
which may slow post-operative recovery.5-7
Randomised clinical trials have shown that
using a gelatine matrix with thrombin to assist
haemostasis decreases the operating time and
intra-operative blood loss of patients undergo-
ing cardiac,8 general,9,10 and ENT surgery.11,12
There are, however, few randomised clinical tri-
als on its use in orthopaedic or spinal surgery.
Renkens et al13 randomised 127 adult patients
undergoing spinal surgery, who failed to
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respond to conventional surgical means of controlling bleed-
ing, into two groups one of which received gelatine matrix
with bovine thrombin and the other Gelfoam (Pfizer, New
York City, New York) soaked in bovine thrombin. They
found that bleeding was controlled faster with the gelatine
matrix sealant: 98% of patients who received this product
stopped bleeding within ten minutes compared with 90% of
the Gelfoam group. 
Two randomised clinical trials have shown reduced
intra-operative blood loss in patients undergoing total
knee arthroplasty.14,15 The effects on post-operative
drainage are controversial. Some studies have shown
reduced blood loss14,15 and another no effect.16 There
have also been two studies in children undergoing ade-
noidectomy or adenotonsillectomy, in which it was shown
that gelatine matrix reduced both intra-operative blood
loss and operating time.11,12 In addition to increased cost,
the use of gelatine matrix has been associated with rare
but severe peri-operative complications.17-20 Anaphylaxis
has occurred during posterior17 and anterior surgery for
spinal deformity.18 There have also been two reports of
epidural spinal cord compression with neurological defi-
cits. Both of these were associated with the intrapedicular
application of gelatine matrix during pedicle screw inser-
tion. Both needed urgent surgical evacuation of
intraspinal haematoma.19 
Although there have been no clinical trials of gelatine
matrix with human thrombin in paediatric orthopaedic
surgery, it has been widely used in children undergoing sur-
gery for spinal deformity.4,17,19,21-23 It has been applied top-
ically to enhance haemostasis when conventional surgical
techniques have failed or were difficult to apply. 
The purpose of this randomised trial was to verify the
efficacy of adding gelatine matrix to conventional surgical
methods of addressing blood loss in adolescents undergo-
ing surgical correction of an idiopathic scoliosis. We
hypothesised that gelatine matrix with human thrombin
would be more effective at reducing operative blood loss
than conventional surgical methods alone. 
Patients and Methods
Study design. We conducted a randomised, multicentre,
clinical trial according to CONSORT criteria24 at three
major university hospitals in Finland. The trial was regis-
tered at ClinicalTrials.gov (NCT01451788).
Ethical permission was obtained from the Ethics Com-
mittee of the primary hospital at which the study was con-
ducted. All patients gave their informed consent.
The study was carried out between January 2012 and
December 2014. The trial ended when all patients had been
enrolled and operated on and had completed follow-up by
December 2014.
Excluded (n = 30)
Not meeting criteria (n = 0)
Declined to participate (n = 30)
Other reasons (n = 0)
Randomised (n = 60)
Enrolment
Allocation
Analysis
Allocated to intervention (n = 30)
Gelatin matrix with human thrombin
Received allocated intervention (n = 30)
Did not receive allocated intervention (n = 0)
Allocated to control (n = 30)
Control group
Received allocated intervention (n = 29)
Did not receive allocated intervention (n = 1)
(safety aspect, > 50% blood loss)
Follow-up
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysed (n = 30)
Excluded from analysis (n = 0)
Analysed (n = 30)
Excluded from analysis (n = 0)
Assessed for eligibility (n = 90)
Fig. 1
Consolidated Standards of Reporting Trials (Consort) 24 flow chart.
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The two treatment groups consisted of adolescents
undergoing posterior surgery for an idiopathic scoliosis of
between 45° and 90°.
Patients were included if they fulfilled the following cri-
teria: between ten and 21 years of age; no contraindication
to the use of gelatine matrix with human-derived thrombin;
suitable for posterior scoliosis surgery using a total pedicle
screw technique for AIS (Lenke classification25 Types 1 to 4
or 6); normal blood coagulation; a normal whole spine MRI
except for the spinal deformity (juvenile or AIS) (Fig. 1). 
Exclusion criteria were the need for anteroposterior sur-
gery; the need for vertebral resection; smoking; diabetes mel-
litus or abnormalities in blood coagulation. Pre-operative
donation of autologous blood was not undertaken in any
patient and use of non-steroidal anti-inflammatory medica-
tion was not recommended within one week of surgery. 
The intervention group received gelatine matrix with
human derived thrombin (FloSeal, Baxter United States,
Deerfield, Illinois) while the control group did not. Other-
wise, conventional methods of haemostasis (bone wax;
bipolar diathermy and epidural space packing for epidural
venous bleeding) were used. 
Randomisation to intervention and control groups (1:1)
was carried out using the sealed envelope technique after
the induction of general anaesthesia. 
The main outcome measures were intra-operative blood
loss (mls), drain output over 24 hours (mls), and total
blood loss (intra-operative blood loss + drain output). Sec-
ondary outcome factors included the need for blood prod-
ucts (packed red cells, frozen plasma or platelets),
laboratory measurements (haemoglobin (Hb), haematocrit
(Hct)), operating time, radiological outcomes, hospital stay
and complications.
Intervention . The gelatine matrix with human derived
thrombin (500 IU/ml) (FloSeal, Baxter United States) comes
in units of 5 ml. In the treatment group, the mean number
of units used to stop bleeding was 3.4 (2 to 6). It was
systematically injected into every bleeding pedicle, into the
epidural space in patients who were undergoing the Ponte
procedure26 and onto decorticated bony surfaces. After hae-
mostasis had been achieved, the excess gelatine matrix not
involved in formation of the clot was gently washed away
from both the pedicles and the epidural space with saline.
This took place typically after a minimum of two minutes or
at the end of the procedure. The posterior decorticated bony
elements were not irrigated. For ethical reasons, the gelatine
matrix with human thrombin was used in both the treatment
and control groups when bleeding exceeded 50% of the total
blood volume during surgery, or if it was considered clini-
cally to be in the best interest of the patient.
Patients. A total of 60 patients were enrolled in the study
(Table I, Fig. 1). Pre-operative clinical examination was
undertaken by one of four paediatric spinal surgeons. All
patients were operated by these same spinal surgeons.
Standing posteroanterior and lateral radiographs of the
whole spine were taken pre-operatively and at discharge. At
least two independent observers who were unaware of the
chosen treatment measured the radiographs. Bending radi-
ographs of the spine were taken pre-operatively to identify
structural curves.25 The SRS-24 questionnaire27 was com-
pleted by the patients both pre-operatively and before dis-
charge. All patients underwent an MRI of the whole spine
Table I. Baseline characteristics of enrolled patients
Parameter* Control group (n = 30) Treatment (n = 30) p-value
Age at surgery (yrs) 15.4 (2.1) 16.0 (2.1) 0.28
Gender (M:F) 7:23 10:20 0.34
BMI 19.9 (3.3) 20.6 (3.0) 0.42
Type of scoliosis (n) 0.16
AIS 26 29
JIS 4 1
Lenke type (n)†
 1 10 9
 2 11 10
 3 2 1
 4 2 0
 6 5 10
Estimated blood volume (mls) 3890 (666) 4017 (731) 0.49
No. of levels fused 11.1 (1.3) 11.4 (1.4) 0.40
No. of Ponte procedures 10 9 0.70
No. of screws placed 21.9 (3.0) 22.1 (2.6) 0.78
SRS-24 total score‡
 Pre-operative 4.4 (0.40) 4.3 (0.53) 0.20
 6 months 3.8 (0.41) 3.9 (0.44) 0.45
* The values are given as the mean, with the standard deviation in parenthesis
† Lenke classification for adolescent idiopathic scoliosis25
‡ SRS-24, Scoliosis Research Society 24 outcome questionnaire26 
BMI, body mass index
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and a standard coagulation profile (Hb, Hct, thrombocyte
counts, prothrombin time, INR and activated partial
thromboplastin time). Arterial blood sampling for Hb con-
centration was carried out both during and at the end of the
procedure. The same blood tests were repeated on post-
operative days 1 to 5. 
Surgical technique. Surgical planning of implant placement
and the need for the Ponte procedure26 were carried out
before randomisation. Each patient was placed in the prone
position and the posterior elements were exposed using
electrocautery. The deformity was corrected using bilateral
segmental pedicle screw instrumentation and en bloc verte-
bral column derotation (6.35 CD Legacy or Solera 6.0,
Medtronics Spinal and Biologics, Memphis, Tennessee).4
Spinal fusion was carried out using autograft acquired from
facetectomies and osteotomies with bone graft extenders
(BCP and Nanostim, Medtronics Spinal and Biologics). Spi-
nal cord monitoring (MEP, SSEP, lumbar nerve root EMG
with or without pedicle screw stimulation) was undertaken
in all patients. A single subfascial drain (Hemovac Ch14;
Zimmer, Warsaw, Indiana) was routinely placed during clo-
sure and removed at 24 hours post-operatively.
Anaesthesia. All patients had a general anaesthetic which
included dexmedetomidine, propofol and remifentanil with
the aim of achieving a mean arterial pressure of between 65
mmHg and 75 mmHg during surgery and for the first 24
hours post-operatively. Cefuroxime and Vancomycin were
used as antibiotic prophylaxis. 
All patients received an intravenous bolus of tranexamic
acid (30 mg/kg, maximum dose 1500 mg) within 30 min-
utes before incision and then an infusion (10 mg/kg/h, max-
imum dose 500 mg/h) during surgery. Intra-operative blood
loss was measured and recorded as the amount of blood
collected in the cell saver, surgical wound dressings were
weighed during surgery, but excluding any irrigation with
saline. The cell saver was used in all patients and the
amount of autologous blood returned was measured. Allo-
geneic red blood cells were transfused if the Hb concentra-
tion was below 90 g/L during surgery or during the hospital
stay. Fresh frozen plasma was given if the blood loss
exceeded 50% of the patient’s total blood volume. Platelets
were infused if the blood loss was more than 100% of the
blood volume. The estimated blood volume was calculated
using a formula of 70 ml/kg x weight (kg).28 
Statistical analysis. Values are given as means with standard
deviations. A two-tailed independent t-test was used to cal-
culate the level of significance for continuous variables
(unpaired for between and paired for within group compar-
ison). The chi-squared test was used for categorical variables. 
The risk factors for bleeding (intra-operative and total
blood loss, in mls) were also analysed using a multiple lin-
ear regression model (IBM SPSS statistics v21.0). All clini-
cally relevant risk factors were analysed in a multivariate
model. Only significant risk factors and the number of
operated pedicles were left in the final multivariate model.
A p-value < 0.05 was considered statistically significant.
The sample-size requirement of 30 patients per group
was calculated using a study power of 80%, a type I error
(alpha) of 0.05, and an estimated effect size of 0.7. Effect
size evaluation was based on the assumption that mean (SD)
peri-operative blood loss (the primary endpoint) would be
1000 (SD 600) for the control group and 600 (SD 600) for
the treatment group.4,29 
If the surgical procedure could not be performed safely
on a patient in the control group without the use of gelatine
matrix with human thrombin, i.e., >50% intra-operative
blood loss or based on the surgeon’s judgment, its use was
allowed, however, the patient remained in the control
Table II. Radiological outcome
Parameter* Control Treatment p-value
Upper thoracic curve (°)
 Pre-operative 24 (9.5) 22 (11) 0.64
 At discharge 8.6 (5.0) 8.2 (5.3) 0.77
 Correction (%) 61 (22) 62 (53) 0.89
Main thoracic curve (°)
 Pre-operative 52 (8.5) 48 (12) 0.14
 On bending radiograph 40 (9.2) 32 (15) 0.033
 Curve correction (%) 25 (14) 26 (24) 0.049
 At discharge 12 (4.1) 12 (5.5) 0.96
 Correction (%) 78 (7.2) 75 (10) 0.35
Lumbar curve (°)
 Pre-operative 38 (15) 38 (13) 0.93
 At discharge 12 (7.5) 11 (8.1) 0.58
 Correction (%) 67 (15) 72 (19) 0.33
Thoracic kyphosis (Th5-Th12, (°))
 Pre-operative 16 (11) 23 (10) 0.10
 At discharge 19 (6.7) 18 (7.0) 0.52
Lumbar lordosis (T12-S1, (°))
 Pre-operative 49 (12) 51 (11) 0.59
 At discharge 49 (10) 47 (10) 0.46
* The values are given as means, with the standard deviation in parentheses
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group for statistical comparison on the intention-to-treat
principle.24 
Results
Peri-operative and transfusion data. The baseline character-
istics of the enrolled patients are shown in (Table I). The
mean pre-operative major curve in the control group was
55° (45° to 75°) and was corrected to 12° (6° to 25°). The
mean pre-operative major curve in the intervention group
was 53° (45° to 77°) and was corrected to 13° (4° to 24°;
p = 0.96). The groups were similar at baseline with one
exception; the control group had significantly less correc-
tion in the main thoracic curves on bending radiographs
than the treatment group (p = 0.033) (Table II). Two
patients in each group received an allogeneic red blood cell
transfusion during surgery and three patients in each group
post-operatively (Table III). One patient in the control
group received two units of gelatine matrix with thrombin
during surgery based on the safety criteria (> 50% blood
loss). One patient in the treatment group received more
than four units of gelatine matrix with human thrombin
(six units) to reduce excessive intra-operative blood loss.
Blood loss. Both the intra-operative blood loss and the total
blood loss increased with the duration of the operation
(Fig. 2, Tables III to V). 
There were no statistically significant differences in the
post-operative laboratory values between the study groups
with one exception: the control group had significantly
lower Hb and Hct values on the second post-operative day
compared with the treatment group (Table III).
Due to the relationship between blood loss and duration
of surgery, the effect of treatment and other risk factors on
bleeding were analysed using a multiple linear regression
model (Table V). Every hour of operating increased the intra-
operative blood loss by a mean 356.9 ml (95% confidence
interval (CI) 273 to 440) and the total blood loss by a mean
430.5 ml (95% CI 343 to 518) (Table V). After adjusting for
duration of operation and number of pedicles instrumented
the intervention significantly decreased the intra-operative
(-171 ml, 95% CI -320 to -22, p = 0.025) and total blood
loss (-177 ml, 95% CI -333 to -21, p = 0.027) compared
with that of the control group (Table V).
The decrease in haemoglobin concentration from the day
before surgery to the second post-operative day was further
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Fig. 2a
Graphs showing the effect of gelatine matrix with thrombin on bleeding in adolescents undergoing posterior spinal fusion for idiopathic scoliosis:
a) intra-operative blood loss and b) total blood loss.
Fig. 2b
Table III. Laboratory and transfusion data
Parameter* Control group (n = 30) Treatment (n = 30) p-value
Haemoglobin (g/l)
 Pre-operative 139 (11) 138 (9.6) 0.82
 Screw insertion 117 (13) 119 (14) 0.61
 Closing 117 (14) 116 (15) 0.82
 First post-operative day 109 (13) 109 (10) 0.81
 Second post-operative day 96 (11) 101 (10) 0.039
Red blood cell infusion (n)†
 Intra-operative 2 2 1.0
 Post-operative 3 3 1.0
Autologous red blood cell infusion (ml) 123 (127) 110 (135) 0.71
* The values are given as means, with the standard deviation in parenthesis
†Number of patients receiving red blood cell infusion
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characterised by the multiple linear regression model. The
duration of operation did not significantly affect the
decrease in Hb, but every pedicle instrumented decreased
the post-operative Hb by 2.6 g/l (Table V). The addition of
gelatine matrix with human thrombin significantly reduced
the decrease in the post-operative Hb by 6 g/L (Table V). 
Length of stay and complications. The length of stay in
hospital was similar in both groups (7.1 vs 7.3 days,
p = 0.53). No adverse effects related to use of gelatine
matrix with human thrombin were reported and there was
no acute deep wound infections or neurological deficits in
either group. 
Discussion
In accordance with the previous findings of Renkens et al13
on faster surgical haemostasis with thrombin based sealant,
we demonstrate here that the use of gelatine matrix with
human thrombin decreases both the intra- and post-opera-
tive blood loss when added to traditional means to address
surgical bleeding in adolescents undergoing surgery for idi-
opathic scoliosis.
The mean post-operative drainage was slightly greater in
the intervention group than in the control group, although
small differences in the basic demographic variables such as
BMI and the inclusion of more Lenke 6 curves may have
contributed to this. However, when adjusted for the num-
ber of pedicles instrumented and the duration of operation,
the treatment group had a mean of 6 ml less blood loss
post-operatively. It is therefore possible that gelatine matrix
may decrease the continuing post-operative blood loss from
exposed and decorticated posterior spinal elements and / or
the epidural space, as the treatment group also in our study
had significantly higher Hb and Hct values on the second
post-operative day. 
A halo effect is a possible confounding factor in ran-
domised controlled studies. The haemostasis in the control
group may be better than normal, which may also reduce
the observed differences between the study groups.
Orthopaedic surgeons who undertake surgery for spinal
deformity need to consider whether the product is cost
effective as well as reflecting on possible adverse effects
such as anaphylaxis.17,18 One patient in the control group
Table IV. Blood loss and operating time in the control and treatment groups
Parameter* Control (n = 30) Treatment (n = 30) p-value
Blood loss (mls) 597 (410) 533 (475) 0.57
 % of blood volume 16 (10) 14 (14) 0.60
 Per level 54 (37) 45 (37) 0.40
 Per screw 28 (24) 24 (19) 0.40
 Per degree 11 (6.0) 9.6 (7.3) 0.60
Drain output (mls) 513 (169) 532 (151) 0.64
 % of blood volume 14 (5.2) 14 (5.1) 0.91
 Per level 46 (13) 47 (13) 0.77
 Per screw 23 (6.8) 24 (6.9) 0.62
 Per degree 9.5 (3.3) 10 (2.7) 0.33
Total blood loss (mls)† 1110 (459) 1065 (563) 0.74
 % of blood volume 29 (12) 28 (18) 0.70
 Per level 100 (40) 92 (44) 0.51
 Per screw 52 (26) 48 (22) 0.54
 Per degree 20 (7.0) 20 (8.2) 0.94
Operating time (hrs) 3.0 (0.80) 3.3 (1.1) 0.25
 Per level 0.27 (0.072) 0.29 (0.086) 0.42
 Per screw 0.14 (0.047) 0.15 (0.043) 0.45
 Per degree 0.054 (0.011) 0.062 (0.016) 0.039
*The values are given as means, with the standard deviation in parenthesis.
† Total blood loss consisted of the intra-operative blood loss and the drain output 
over 24 hours post-operatively.
Table V. Multivariate analyses on the effect of gelatine matrix with human thrombin on intra-operative, total blood loss, and post-operative decrease
in haemoglobin concentration*
Risk factor Intra-operative blood loss Total blood loss
Post-operative decrease in 
haemoglobin concentration 
β (mls) 95% CI p-value β (mls) 95% CI p-value β (g/l) 95% CI p-value
Pedicles instrumented (blood loss or haemoglobin 
decrease per pedicle)
19.7 -37.6 to 77.1 0.49 35.6 -24.5 to 95.7 0.24 2.6 0.7 to 4.5 0.008
Operating time (blood loss or haemoglobin decrease 
per hour)
356.9 273 to 440 < 0.001 431 343 to 518 < 0.001 1.9 -0.7 to 4.5 0.15
Intervention -171 -320 to -22 0.025 -177 -333 to -21 0.027 -6.0 -10.7 to -1.3 0.013
* Analysed with multiple linear regression model 
CI, confidence interval
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was given gelatine matrix with thrombin to address an
intra-operative blood loss of > 50% of the circulating vol-
ume. Given that a similar number of patients in both
groups received allogeneic blood transfusions, the average
additional cost of gelatine matrix used per patient would be
£11 in the control group and £575 in the treatment group.
There are risks of using the cell saver with gelatine
matrix.30 Gelatine matrix with human thrombin should not
be drained directly into the cell saver. Despite irrigation,
fragments of gelatine matrix may enter through the
transfusion filters of the blood scavenging systems and
become mixed with the autologous blood. Blood from the
cell saver should also be transfused slowly to reduce the risk
of anaphylaxis.
In conclusion, the use of gelatine matrix with human
thrombin reduces both intra-operative blood loss and the
post-operative decrease in haemoglobin concentration in
adolescents undergoing surgery for idiopathic scoliosis
when added to conventional methods of addressing blood
loss. Based on the current findings, we recommend its use in
adolescents undergoing posterior spinal fusion for idio-
pathic scoliosis.
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